ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

Core Viewpoint - ProMIS Neurosciences, Inc. is actively engaging with investors and the healthcare community through participation in the 8th Annual Evercore Healthcare Conference, highlighting its focus on developing innovative therapies for Alzheimer's disease and other neurodegenerative disorders [1][2]. Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company dedicated to discovering and developing therapeutic antibodies and vaccines that target toxic oligomers associated with neurodegenerative diseases, including Alzheimer's disease, ALS, FTD, MSA, and PD [3]. - The company utilizes its proprietary EpiSelect™ target discovery engine to identify Disease Specific Epitopes (DSEs) on misfolded proteins, which are crucial for developing targeted therapies [3]. Product Development - PMN310 is the lead product candidate designed as a humanized monoclonal antibody that selectively targets toxic oligomers while avoiding plaque, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA) [4]. - PMN310 received Fast Track designation from the U.S. FDA in July 2025, indicating its potential significance in treating Alzheimer's disease [4]. Clinical Trials - Following positive results from the Phase 1a trial, ProMIS initiated the PRECISE-AD Phase 1b clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease [5]. - The PRECISE-AD trial is designed as a randomized, double-blind, placebo-controlled study, focusing on the effects of PMN310 on biomarkers and clinical outcomes associated with Alzheimer's disease [5]. EpiSelect Drug Discovery Engine - The EpiSelect platform enables the identification of conformational epitopes on toxic misfolded proteins, facilitating the development of highly selective therapeutic antibodies and vaccines [6]. - PMN310 has demonstrated high selectivity for toxic amyloid-beta oligomers without significant reactivity with other forms, potentially minimizing adverse effects associated with conventional therapies [6].